Staged HMO Nutritional Compositions for Infant Gut Microbiota
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutritional compositions for infants do not adequately mimic the changing composition of human breast milk as the infant ages, which is essential for optimal gut microbiota development and overall health.
Innovation Solution
Development of age-specific nutritional compositions comprising human milk oligosaccharides (HMOs) such as 2′-fucosyllactose, 3′-fucosyllactose, lacto-N-tetraose, 6′-sialyllactose, and 3′-sialyllactose, tailored to different age stages (0-6 months, 6-12 months, and 0-3 months) to mirror the varying levels found in breast milk at different lactation stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If constant level of HMOs is provided throughout infant development, then manufacturing simplicity is maintained, but nutritional adequacy deteriorates
Solution Approach 1:
The patent divides infant nutrition into distinct age stages (0-6 months, 6-12 months, 1-3 years) with each stage having specific HMO composition requirements. This segmentation allows the formulation to match the dynamic changes in breast milk composition at different lactation stages, resolving the contradiction between manufacturing simplicity and nutritional adequacy by creating standardized stage-specific formulations.
Solution Approach 2:
The patent implements dynamic HMO composition that changes with infant age, mirroring the natural changes in breast milk composition during lactation. The formulation transitions from high 2'-FL content in early stages to increased 3'-FL and sialylated HMOs in later stages, ensuring nutritional adequacy while maintaining manageable manufacturing processes through defined stage protocols.
2Reliability
If HMO composition is tailored to different age stages, then nutritional adequacy is improved, but device complexity increases
Solution Approach 1:
The patent systematically changes HMO parameters (composition ratios, concentrations) across different age stages to match physiological development. Stage 1 (0-6 months) emphasizes 2'-FL for initial microbiota establishment, while Stage 2 (6-12 months) increases 3'-FL and sialylated HMOs for advanced brain development, creating a managed complexity structure that follows defined parameter progression.
Solution Approach 2:
The patent applies different HMO composition profiles to different age stages based on specific developmental needs. Each stage receives a customized HMO profile (e.g., Stage 1: high 2'-FL for Bifidobacterium establishment; Stage 3: high sialylated HMOs for neural development), ensuring local optimization without requiring complete reformulation of the entire product line.
3Reliability
If breast milk composition is mimicked at different lactation stages, then gut microbiota development is improved, but manufacturing complexity increases
Solution Approach 1:
The patent creates simplified copies of breast milk HMO composition at different lactation stages using standardized synthetic or extracted HMO components. Rather than replicating the full complexity of natural breast milk, the formulation uses key representative HMOs (2'-FL, 3'-FL, sialylated HMOs) in stage-specific ratios that capture the essential functional characteristics while maintaining manufacturing feasibility.
Data Source
AI summary
The present application provides nutritional compositions comprising human milk oligosaccharides, for use in providing nutrition to infants at different age stages.